Skip to Content

The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.

Alizapride

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

A03FA05

CAS registry number (Chemical Abstracts Service)

0059338-93-1

Chemical Formula

C16-H21-N5-O2

Molecular Weight

315

Therapeutic Categories

Antiemetic agent

Dopamine agonist

Chemical Name

N-[(1-Allyl-2-pyrrolidinyl)metyl]-6-metoxy-1H-benzotriazole-5-carboxamide (WHO)

Foreign Names

  • Alizapridum (Latin)
  • Alizaprid (German)
  • Alizapride (French)
  • Alizaprida (Spanish)

Generic Name

  • Alizapride (OS: DCIT, DCF)

Brand Names

  • Alizaprida Humax
    Humax, Colombia
  • Nausilex
    Minapharm, Egypt
  • Limican
    Pharmafar, Italy
  • Litican
    Sanofi Belgium, Belgium
  • Litican 50mg
    Sanofi Belgium, Luxembourg
  • Litican 50mg/2ml
    Sanofi Belgium, Luxembourg
  • Plitican
    Sanofi-Aventis, Colombia; Sanofi-Aventis, France; Sanofi-Aventis, Kuwait
  • Plitivan
    Sanofi-Aventis, Colombia
  • Superan
    Sanofi-Aventis Farmaceutica, Brazil
  • Vergentan
    Sanofi-Aventis Deutschland, Germany

Glossary

TermDefinition
DCFDénomination Commune Française
DCITDenominazione Comune Italiana
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.